Looking for a Breakthrough in Alzheimer’s Disease
April 11th, 2023
Lara Stefansson is a PhD student in neuroscience and a trainee in Georgetown’s Pharmacological Sciences Training Program. See her article from 6 April 2023 on Alzheimer’s treatments,…
Treatment with solanezumab is not effective in preventing Alzheimer’s disease
March 14th, 2023
Katie Seidenberg and R. Scott Turner Eli Lilly and collaborators released the topline results of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study March…
Lecanumab (LeqembiTM) FDA-approved for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD) – collectively called early AD R. Scott Turner
January 20th, 2023
R. Scott Turner A breakthrough, finally! Leqembi is the first disease-modifying treatment for individuals with MCI and mild AD with solid evidence of effectiveness. Thus, Leqembi (previously…
Following this Four-Pillar Program may delay the onset, slow down, or prevent dementia and AD by 5-10 years. But if all pillars are followed, life expectancy may also increase by 5-10 years, and the #1 risk factor for cognitive decline and dementia is aging. However, compliance will restore balance and maintain cognitive performance with aging. Adhering to only part of the Program may be less effective or ineffective. The goal is to maximize health-span and lifespan while minimizing years of disability (cognitive and/or physical) at end-of-life.
Memory Cafe is a casual social meeting venue for those with progressive memory or cognitive impairment and their caregivers. A Memory Cafe is a place where caring individuals come together to find resources, support, companionship, and fun. You can work simple puzzles, play games such as bean bag toss, Yahtzee, etc.
Memory Cafes in the Washington DC area:
The Alzheimer’s Association has local support groups that serve DC, Maryland, and Northern Virginia. The National Capital website links to many other online and offline resources offered by the national Alzheimer’s Association, including a 24/7 Helpline, education programs, Trial Match and advocacy resources.
“The Alzheimer’s Disease Education and Referral (ADEAR) Center Web site will help you find current, comprehensive Alzheimer’s disease (AD) information and resources from the National Institute on Aging (NIA).” Their website includes caregivers’ resources and research, as well as general information.
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego. The ADCS is a major initiative for Alzheimer’s disease (AD) clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Neuroscience and Neuropsychology of Aging Program’s effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer’s Disease Prevention Initiative.
The Alzheimer’s Therapeutic Research Institute (ATRI) at the University of Southern California Keck School of Medicine is dedicated to the development of effective treatments for Alzheimer’s disease through innovative, collaborative, multicenter clinical trials. USC ATRI is the Keck School’s clinical outlet for testing of new treatments for Alzheimer’s Disease. Paul Aisen, MD is the founding director of USC ATRI. He was the director of the ADCS until 2015.
Thank you for participating in the Georgetown University Memory Disorders Program 20th Anniversary Celebration. Our goal was to show our appreciation of your efforts to help us combat Alzheimer’s Disease and related disorders. We also sought to educate the community about current trends in Alzheimer’s disease research. It is because of your involvement in the Memory Disorders Program that we can celebrate 20 years of research and clinical care.
On October 17th, 2019 we presented:
Additionally, we seek your feedback regarding the 20th Anniversary Celebration (new window). Thank you to those who completed the questionnaire at the event. If you have additional thoughts you wish to share with us, we would appreciate hearing from you. For those who registered, but did not attend, we welcome your feedback; please share your suggestions on what would motivate you to participate in a future MDP event.
You helped to make this event a success, and your ongoing commitment in fighting Alzheimer’s disease energizes us to move forward in our search for improved care and cures.
For more health, research and clinical trials information, visit the National Institute of Aging and Clinical Trials Directory websites.
